Skip to content
Immigration, Medical Health Aged Care

Frank Overseas Visitor Health Cover recognised for value and service in Finder Customer Satisfaction Awards

Frank Health Insurance < 1 mins read
Key Facts:

Key benefits of Frank OVHC include:

  • Fully visa compliant, meeting the Department of Home Affairs requirements for 482 and 485 visa holders.
  • Four covers to choose from with a range of services to suit member needs.
  • Designed to be simple and transparent, so members can easily understand what’s included in their policy.
  • Members can complete an easy online joining process in just minutes and receive their health insurance compliance letter within 10 minutes.
  • Backed by Frank Health Insurance, a not-for-profit that provides simple and affordable hospital and extras cover

Frank Overseas Visitor Health Cover helps thousands of international visitors and skilled workers arriving in Australia feel covered and confident every year.

Finder has recently recognised Frank’s commitment, awarding it a High Commendation in the Overseas Visitor Health Cover (OVHC) category and naming it a value brand in the 2025 Health Insurance Customer Satisfaction Awards.

The recognition highlights Frank’s focus on making cover for international workers simple, affordable and stress-free as they settle into life in Australia.

Access the full release here: Frank Overseas Visitor Health Cover recognised for value and service in Finder Customer Satisfaction Awards 


Contact details:

Media enquiries 
Head of Corporate Communications Meg Rayner: [email protected] or 0458 418 823

Media

More from this category

  • Medical Health Aged Care
  • 07/12/2025
  • 01:41
Takeda Pharmaceutical Company Limited

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline NEWARK,…

  • Medical Health Aged Care
  • 06/12/2025
  • 02:11
Arthur D. Little

Arthur D. Little and Vega IT Unveil Joint Venture for Digital Innovation

NEW YORK–BUSINESS WIRE– Arthur D. Little (ADL) and Vega IT today announced the formation of Axceler8 Solutions, a 50/50 joint venture created to design,…

  • Contains:
  • Medical Health Aged Care, Women
  • 05/12/2025
  • 10:11
Breast Cancer Trials

Bec’s Christmas wish amid cancer treatment

This Christmas, Bec’s wish is for her daughters to never face a breast cancer diagnosis like she has. “The only thing tougher than telling…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.